Literature DB >> 30984272

Corrigendum to "Toll-Like Receptor 4-Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression".

Qiaomei Dai1, Ji Li2, Yu Yun3, Jianwei Wang4.   

Abstract

[This corrects the article DOI: 10.1155/2018/2428546.].

Entities:  

Year:  2019        PMID： 30984272      PMCID： PMC6431497          DOI： 10.1155/2019/2198708

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN： 1741-427X            Impact factor:   2.629


In the article titled “Toll-Like Receptor 4–Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression” [1], reference [4], J. A. Carlsson et al. [2], was incorrectly included in the reference list and should be replaced with M. F. Roelofs et al. [3].
  3 in total

1.  The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells.

Authors:  M F Roelofs; L A B Joosten; S Abdollahi-Roodsaz; A W T van Lieshout; T Sprong; F H van den Hoogen; W B van den Berg; T R D J Radstake
Journal:  Arthritis Rheum       Date:  2005-08

2.  The Polyunsaturated Fatty Acids Arachidonic Acid and Docosahexaenoic Acid Induce Mouse Dendritic Cells Maturation but Reduce T-Cell Responses In Vitro.

Authors:  Johan A Carlsson; Agnes E Wold; Ann-Sofie Sandberg; Sofia M Östman
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

3.  Toll-Like Receptor 4-Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression.

Authors:  Qiaomei Dai; Ji Li; Yu Yun; Jianwei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-12-16       Impact factor: 2.629
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.